| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1018940730 |
| P356 | DOI | 10.1186/1471-2407-10-515 |
| P932 | PMC publication ID | 2955043 |
| P698 | PubMed publication ID | 20920162 |
| P5875 | ResearchGate publication ID | 47335377 |
| P50 | author | David Hedley | Q54282536 |
| Jeffrey N Miner | Q115235146 | ||
| P2093 | author name string | Mark S Chapman | |
| Qing Chang | |||
| P2860 | cites work | Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer | Q24685746 |
| RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer | Q27657185 | ||
| Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer | Q29618155 | ||
| Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse | Q29620396 | ||
| The two TORCs and Akt. | Q34617423 | ||
| Targeting the mitogen-activated protein kinase cascade to treat cancer | Q35968411 | ||
| The Akt-mTOR tango and its relevance to cancer | Q36260264 | ||
| Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. | Q37177892 | ||
| Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models | Q39763382 | ||
| AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). | Q39775573 | ||
| Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts | Q40220268 | ||
| The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation | Q40432178 | ||
| Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants | Q40439754 | ||
| Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma | Q43279511 | ||
| Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. | Q43763050 | ||
| Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. | Q43770303 | ||
| Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xe | Q45285589 | ||
| Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression | Q46868532 | ||
| The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo | Q72789935 | ||
| An in vivo platform for translational drug development in pancreatic cancer | Q80087890 | ||
| P4510 | describes a project that uses | ImageQuant | Q112270642 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pancreatic cancer | Q212961 |
| sirolimus | Q32089 | ||
| xenograft | Q64148587 | ||
| P304 | page(s) | 515 | |
| P577 | publication date | 2010-09-28 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts | |
| P478 | volume | 10 |
| Q47098844 | Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma |
| Q24608066 | Graviola: A novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism |
| Q39119302 | Imaging Mass Cytometry |
| Q34406302 | K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo |
| Q34036341 | MEK and the inhibitors: from bench to bedside |
| Q37872791 | MEK inhibitors: a patent review 2008 – 2010 |
| Q38179145 | MEK1/2 inhibitors in the treatment of gynecologic malignancies. |
| Q89086204 | Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells |
| Q36174910 | Molecular targeted approaches for treatment of pancreatic cancer. |
| Q27852097 | Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer |
| Q26787087 | Novel agents for advanced pancreatic cancer |
| Q37828536 | Novel mitogen-activated protein kinase kinase inhibitors |
| Q38193520 | Prospects for MEK inhibitors for treating cancer. |
| Q34307356 | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance |
| Q39426747 | Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: A potential mechanism of therapeutic limitation of mTOR inhibitor |
| Q35018805 | Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models |
| Q35537413 | Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle |
| Q38053855 | Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. |
| Q38270129 | The biology and clinical development of MEK inhibitors for cancer |
Search more.